June 2018 – PHA’s 2018 International PH Conference and Scientific Sessions
Getagozumab: A Therapeutic Monoclonal Antibody Targeting Endothelin Receptor A for Pulmonary Arterial Hypertension
Poster number: 1013


June 2018 – ADA 2018
A phase 1b/2a study of Glutazumab for the treatment of type 2 diabetes and obesity
Abstract number: 2298-PUB


Biochemical Pharmacology 2018
Caina Li, et al. Glutazumab, a novel long-lasting GLP-1/anti-GLP-1R antibody fusion protein, exerts anti-diabetic effects through targeting dual receptor binding sites. Biochemical Pharmacology 150 (2018) 46-53


December 2017 – IDF Congress 2017

A phase I study to investigate the safety, tolerability and pharmacokinetics of a biased GLP-1R antibody Glutazumab

Abstract number: AD-1719

Poster number: P-0352